Literature DB >> 26409036

Chemoreflex and baroreflex alterations in Parkinsonism induced by 6-OHDA in unanesthetized rats.

Deborah Ariza1, Fernanda Novi Cortegoso Lopes1, Carlos Cesar Crestani2, Marli Cardoso Martins-Pinge3.   

Abstract

Parkinson's disease (PD) is mainly characterized by motor signals. However, non-motor signals also affect and decrease the quality of life of PD patients. Among these non-motor signs are cardiovascular disorders as orthostatic hypotension, postprandial hypotension and cardiac arrhythmias, which may be due to the involvement of both central nervous system and peripheral autonomic nervous system. In the present study we investigated the cardiovascular function, evaluating cardiovascular reflexes (chemoreflex and baroreflex), in an animal model of Parkinsonism induced by bilateral infusion of the toxin 6-hydroxydopamine (6-OHDA), in the substantia nigra pars compacta (SNpc). The results showed that the animals induced to Parkinsonism had lower arterial pressure (AP) and heart rate HR) compared to control animals. We showed that after activation of the baroreceptors by phenylephrine (Phe) and sodium nitroprusside (SNP), the baroreflex sensitivity index was not changed between the groups. However, there was a greater increase in the AP when stimulated with Phe and greater tachycardia when stimulated with SNP in 6-OHDA animals. After activation of the peripheral chemoreceptors through KCN injection (cytotoxic hypoxia), there was a higher increase in pressor and bradycardic response in injured animals with bilateral 6-OHDA. These changes in the cardiovascular reflexes may be important adjustments mechanisms to maintain the cerebral blood flow in those animals, and may be a result of denervation supersensitivity to catecholamines in autonomic targets.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Arterial pressure; Dysautonomia; Heart rate; Phenylephrine; Potassium cyanide; Sodium nitroprusside

Mesh:

Substances:

Year:  2015        PMID: 26409036     DOI: 10.1016/j.neulet.2015.09.024

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

1.  Cardiovascular alterations in rats with Parkinsonism induced by 6-OHDA and treated with Domperidone.

Authors:  Laís D Rodrigues; Leandro F Oliveira; Lucas Shinoda; Carla A Scorza; Jean Faber; Henrique B Ferraz; Luiz R G Britto; Fulvio A Scorza
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

Review 2.  Altered cardiorespiratory regulation during exercise in patients with Parkinson's disease: A challenging non-motor feature.

Authors:  Jeann L Sabino-Carvalho; Lauro C Vianna
Journal:  SAGE Open Med       Date:  2020-05-06

3.  6-hydroxydopamine and ovariectomy has no effect on heart rate variability parameters of females.

Authors:  Tomás de la Rosa; Viviam Sanabria Calvo; Valeria Cassia Gonçalves; Débora Amado Scerni; Fúlvio Alexandre Scorza
Journal:  Clinics (Sao Paulo)       Date:  2021-10-11       Impact factor: 2.365

Review 4.  Nitric Oxide Involvement in Cardiovascular Dysfunctions of Parkinson Disease.

Authors:  Marli Cardoso Martins-Pinge; Lorena de Jager; Blenda Hyedra de Campos; Lorena Oliveira Bezerra; Pamela Giovana Turini; Phileno Pinge-Filho
Journal:  Front Pharmacol       Date:  2022-07-11       Impact factor: 5.988

5.  Propolis as A Potential Disease-Modifying Strategy in Parkinson's Disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model.

Authors:  Valeria C Gonçalves; Daniel J L L Pinheiro; Tomás de la Rosa; Antônio-Carlos G de Almeida; Fúlvio A Scorza; Carla A Scorza
Journal:  Nutrients       Date:  2020-05-26       Impact factor: 5.717

Review 6.  Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence.

Authors:  Lorena Cuenca-Bermejo; Pilar Almela; Javier Navarro-Zaragoza; Emiliano Fernández Villalba; Ana-María González-Cuello; María-Luisa Laorden; María-Trinidad Herrero
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.